{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:35:55Z","timestamp":1788291355802,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["Grant Number JP20H03592"],"award-info":[{"award-number":["Grant Number JP20H03592"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00262-021-03053-9","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T04:03:02Z","timestamp":1631505782000},"page":"769-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies"],"prefix":"10.1007","volume":"71","author":[{"given":"Morinobu","family":"Seki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehisa","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-4574","authenticated-orcid":false,"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"3053_CR1","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/jco.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"3053_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"3053_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","volume":"100","author":"M Seki","year":"2019","unstructured":"Seki M, Uruha A, Ohnuki Y et al (2019) Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100:105\u2013113. https:\/\/doi.org\/10.1016\/j.jaut.2019.03.005","journal-title":"J Autoimmun"},{"key":"3053_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","volume":"91","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Muniz-Castrillo S, Joubert B et al (2020) Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 91:772\u2013778. https:\/\/doi.org\/10.1136\/jnnp-2020-323055","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3053_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI et al (2019) A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 25:1243\u20131250. https:\/\/doi.org\/10.1038\/s41591-019-0523-2","journal-title":"Nat Med"},{"key":"3053_CR6","doi-asserted-by":"publisher","first-page":"2548528","DOI":"10.1155\/2018\/2548528","volume":"2018","author":"S Shah","year":"2018","unstructured":"Shah S, Dunn-Pirio A, Luedke M, Morgenlander J, Skeen M, Eckstein C (2018) Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med 2018:2548528. https:\/\/doi.org\/10.1155\/2018\/2548528","journal-title":"Case Rep Neurol Med"},{"key":"3053_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1136\/jnnp-2020-323212","volume":"91","author":"S Suzuki","year":"2020","unstructured":"Suzuki S (2020) Encephalitis as an immune-related adverse event. J Neurol Neurosurg Psychiatry 91:680. https:\/\/doi.org\/10.1136\/jnnp-2020-323212","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3053_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73:928\u2013933. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1399","journal-title":"JAMA Neurol"},{"key":"3053_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000604","author":"A Vogrig","year":"2019","unstructured":"Vogrig A, Fouret M, Joubert B et al (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000604","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3053_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16:535\u2013548. https:\/\/doi.org\/10.1038\/s41571-019-0194-4","journal-title":"Nat Rev Clin Oncol"},{"key":"3053_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/fcp.12349","volume":"32","author":"M Yelehe-Okouma","year":"2018","unstructured":"Yelehe-Okouma M, Czmil-Garon J, Pape E, Petitpain N, Gillet P (2018) Drug-induced aseptic meningitis: a mini-review. Fundam Clin Pharmacol 32:252\u2013260. https:\/\/doi.org\/10.1111\/fcp.12349","journal-title":"Fundam Clin Pharmacol"},{"key":"3053_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10213-x","author":"K Okada","year":"2020","unstructured":"Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, Yamada S, Oki K, Nakahara J, Suzuki S (2020) Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10213-x","journal-title":"J Neurol"},{"key":"3053_CR13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) Antibodies. JAMA Neurol 74:1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"3053_CR14","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, David WS, Amato AA et al (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93:e1093\u2013e1103. https:\/\/doi.org\/10.1212\/WNL.0000000000008091","journal-title":"Neurology"},{"key":"3053_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011340","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Muniz-Castrillo S, Joubert B et al (2020) Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000011340","journal-title":"Neurology"},{"key":"3053_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316510","author":"Y Fukumoto","year":"2017","unstructured":"Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S (2017) Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2017-316510","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3053_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jjco\/hyw090","volume":"46","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y et al (2016) Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J Clin Oncol 46:875\u2013878. https:\/\/doi.org\/10.1093\/jjco\/hyw090","journal-title":"Jpn J Clin Oncol"},{"key":"3053_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","volume":"375","author":"MF de Maleissye","year":"2016","unstructured":"de Maleissye MF, Nicolas G, Saiag P (2016) Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375:296\u2013297. https:\/\/doi.org\/10.1056\/NEJMc1515584","journal-title":"N Engl J Med"},{"key":"3053_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7:319. https:\/\/doi.org\/10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"3053_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/wnl.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134. https:\/\/doi.org\/10.1212\/wnl.0000000000004359","journal-title":"Neurology"},{"key":"3053_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D, Hojgaard JLS, Kondziella D (2019) Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92:663\u2013674. https:\/\/doi.org\/10.1212\/WNL.0000000000007235","journal-title":"Neurology"},{"key":"3053_CR22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2169\/internalmedicine.9153-17","volume":"57","author":"A Mitsune","year":"2018","unstructured":"Mitsune A, Yanagisawa S, Fukuhara T, Miyauchi E, Morita M, Ono M, Tojo Y, Ichinose M (2018) Relapsed myasthenia gravis after nivolumab treatment. Intern Med 57:1893\u20131897. https:\/\/doi.org\/10.2169\/internalmedicine.9153-17","journal-title":"Intern Med"},{"key":"3053_CR23","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/wnl.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985\u2013e994. https:\/\/doi.org\/10.1212\/wnl.0000000000006124","journal-title":"Neurology"},{"key":"3053_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/art.41604","author":"J Aldrich","year":"2020","unstructured":"Aldrich J, Pundole X, Tummala S, Palaskas N, Andersen CR, Shoukier M, Abdel-Wahab N, Deswal A, Suarez-Almazor ME (2020) Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41604","journal-title":"Arthritis Rheumatol"},{"key":"3053_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-019-0811-3","volume":"21","author":"H Kadota","year":"2019","unstructured":"Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, Kuwana M (2019) Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr Rheumatol Rep 21:10. https:\/\/doi.org\/10.1007\/s11926-019-0811-3","journal-title":"Curr Rheumatol Rep"},{"key":"3053_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s40425-019-0736-4","volume":"7","author":"S Matsubara","year":"2019","unstructured":"Matsubara S, Seki M, Suzuki S, Komori T, Takamori M (2019) Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors. J Immunother Cancer 7:256. https:\/\/doi.org\/10.1186\/s40425-019-0736-4","journal-title":"J Immunother Cancer"},{"key":"3053_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","volume":"41","author":"T Liewluck","year":"2018","unstructured":"Liewluck T, Kao JC, Mauermann ML (2018) PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 41:208\u2013211","journal-title":"J Immunother"},{"key":"3053_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25708","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"3053_CR29","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"3053_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/circulationaha.118.035898","volume":"138","author":"C Anquetil","year":"2018","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B et al (2018) Immune checkpoint inhibitor-associated myositis. Circulation 138:743\u2013745. https:\/\/doi.org\/10.1161\/circulationaha.118.035898","journal-title":"Circulation"},{"key":"3053_CR31","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","volume":"9","author":"K Kufukihara","year":"2019","unstructured":"Kufukihara K, Watanabe Y, Inagaki T, Takamatsu K, Nakane S, Nakahara J, Ando Y, Suzuki S (2019) Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis. Sci Rep 9:5284. https:\/\/doi.org\/10.1038\/s41598-019-41730-z","journal-title":"Sci Rep"},{"key":"3053_CR32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/annonc\/mdw655","volume":"28","author":"CL Haddox","year":"2017","unstructured":"Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, Wijdicks EF, Goetz MP (2017) Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 28:673\u2013675. https:\/\/doi.org\/10.1093\/annonc\/mdw655","journal-title":"Ann Oncol"},{"key":"3053_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","volume":"4","author":"MA Bilen","year":"2016","unstructured":"Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P (2016) Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36. https:\/\/doi.org\/10.1186\/s40425-016-0139-8","journal-title":"J Immunother Cancer"},{"key":"3053_CR34","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/acn3.654","volume":"5","author":"K Takamatsu","year":"2018","unstructured":"Takamatsu K, Nakane S, Suzuki S et al (2018) Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol 5:1421\u20131427. https:\/\/doi.org\/10.1002\/acn3.654","journal-title":"Ann Clin Transl Neurol"},{"key":"3053_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"3053_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M et al (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28:377\u2013385. https:\/\/doi.org\/10.1093\/annonc\/mdw558","journal-title":"Ann Oncol"},{"key":"3053_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"3053_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51213","author":"H Chang","year":"2020","unstructured":"Chang H, Shin YW, Keam B, Kim M, Im SA, Lee ST (2020) HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.51213","journal-title":"Ann Clin Transl Neurol"},{"key":"3053_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"3053_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"key":"3053_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376. https:\/\/doi.org\/10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03053-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03053-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03053-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T21:11:29Z","timestamp":1659042689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03053-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03053-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}